New directions in the development of antidepressants

The interface of neurobiology and psychiatry

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

There have been considerable advances in neurobiology in recent years that are providing new directions for the development of novel classes of antidepressants. For example, the finding that corticotropin-releasing factor (CRF) is hypersecreted in depressed patients and mediates certain symptoms of depression has led to the development of specific antagonists of the CRF1 receptor. These are expected to prove highly effective for the treatment of mood and anxiety disorders. Another related avenue of research is based on evidence that cortisol is integral to the pathophysiology of major depression with psychotic features. One alternative for treating this subtype of affective disorder is, therefore, to block the action of glucocorticoids using a receptor antagonist such as mifepristone. These are just two of the many new directions that will likely lead to the development of antidepressants in the near future.

Original languageEnglish
JournalHuman Psychopharmacology
Volume17
Issue numberSUPPL. 1
DOIs
StatePublished - Jul 4 2002
Externally publishedYes

Fingerprint

Neurobiology
Mood Disorders
Antidepressive Agents
Psychiatry
Depression
Mifepristone
Corticotropin-Releasing Hormone
Anxiety Disorders
Glucocorticoids
Hydrocortisone
Research
Direction compound
Therapeutics
CRF receptor type 1

Keywords

  • Antidepressants
  • CRF receptors
  • Depression
  • Glucocorticoid receptors
  • Psychotic depression

ASJC Scopus subject areas

  • Pharmacology
  • Psychology(all)
  • Neuroscience(all)
  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neurology
  • Clinical Neurology

Cite this

New directions in the development of antidepressants : The interface of neurobiology and psychiatry. / Nemeroff, Charles.

In: Human Psychopharmacology, Vol. 17, No. SUPPL. 1, 04.07.2002.

Research output: Contribution to journalArticle

@article{0bddc060a2ce4a77860b1a00040c3c1a,
title = "New directions in the development of antidepressants: The interface of neurobiology and psychiatry",
abstract = "There have been considerable advances in neurobiology in recent years that are providing new directions for the development of novel classes of antidepressants. For example, the finding that corticotropin-releasing factor (CRF) is hypersecreted in depressed patients and mediates certain symptoms of depression has led to the development of specific antagonists of the CRF1 receptor. These are expected to prove highly effective for the treatment of mood and anxiety disorders. Another related avenue of research is based on evidence that cortisol is integral to the pathophysiology of major depression with psychotic features. One alternative for treating this subtype of affective disorder is, therefore, to block the action of glucocorticoids using a receptor antagonist such as mifepristone. These are just two of the many new directions that will likely lead to the development of antidepressants in the near future.",
keywords = "Antidepressants, CRF receptors, Depression, Glucocorticoid receptors, Psychotic depression",
author = "Charles Nemeroff",
year = "2002",
month = "7",
day = "4",
doi = "10.1002/hup.396",
language = "English",
volume = "17",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - New directions in the development of antidepressants

T2 - The interface of neurobiology and psychiatry

AU - Nemeroff, Charles

PY - 2002/7/4

Y1 - 2002/7/4

N2 - There have been considerable advances in neurobiology in recent years that are providing new directions for the development of novel classes of antidepressants. For example, the finding that corticotropin-releasing factor (CRF) is hypersecreted in depressed patients and mediates certain symptoms of depression has led to the development of specific antagonists of the CRF1 receptor. These are expected to prove highly effective for the treatment of mood and anxiety disorders. Another related avenue of research is based on evidence that cortisol is integral to the pathophysiology of major depression with psychotic features. One alternative for treating this subtype of affective disorder is, therefore, to block the action of glucocorticoids using a receptor antagonist such as mifepristone. These are just two of the many new directions that will likely lead to the development of antidepressants in the near future.

AB - There have been considerable advances in neurobiology in recent years that are providing new directions for the development of novel classes of antidepressants. For example, the finding that corticotropin-releasing factor (CRF) is hypersecreted in depressed patients and mediates certain symptoms of depression has led to the development of specific antagonists of the CRF1 receptor. These are expected to prove highly effective for the treatment of mood and anxiety disorders. Another related avenue of research is based on evidence that cortisol is integral to the pathophysiology of major depression with psychotic features. One alternative for treating this subtype of affective disorder is, therefore, to block the action of glucocorticoids using a receptor antagonist such as mifepristone. These are just two of the many new directions that will likely lead to the development of antidepressants in the near future.

KW - Antidepressants

KW - CRF receptors

KW - Depression

KW - Glucocorticoid receptors

KW - Psychotic depression

UR - http://www.scopus.com/inward/record.url?scp=0036089270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036089270&partnerID=8YFLogxK

U2 - 10.1002/hup.396

DO - 10.1002/hup.396

M3 - Article

VL - 17

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - SUPPL. 1

ER -